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Abstract | Despite tremendous investments in understanding the complex molecular mechanisms underlying 
Alzheimer disease (AD), recent clinical trials have failed to show efficacy. A potential problem underlying these 
failures is the assumption that the molecular mechanism mediating the genetically determined form of the 
disease is identical to the one resulting in late‑onset AD. Here, we integrate experimental evidence outside 
the ‘spotlight’ of the genetic drivers of amyloid‑β (Aβ) generation published during the past two decades, 
and present a mechanistic explanation for the pathophysiological changes that characterize late‑onset AD. 
We propose that chronic inflammatory conditions cause dysregulation of mechanisms to clear misfolded or 
damaged neuronal proteins that accumulate with age, and concomitantly lead to tau‑associated impairments 
of axonal integrity and transport. Such changes have several neuropathological consequences: focal 
accumulation of mitochondria, resulting in metabolic impairments; induction of axonal swelling and leakage, 
followed by destabilization of synaptic contacts; deposition of amyloid precursor protein in swollen neurites, 
and generation of aggregation‑prone peptides; further tau hyperphosphorylation, ultimately resulting in 
neurofibrillary tangle formation and neuronal death. The proposed sequence of events provides a link between 
Aβ and tau‑related neuropathology, and underscores the concept that degenerating neurites represent a cause 
rather than a consequence of Aβ accumulation in late‑onset AD.
Krstic, D. & Knuesel, I. Nat. Rev. Neurol. 9, 25–34 (2013); published online 27 November 2012; doi:10.1038/nrneurol.2012.236
Introduction
Alzheimer disease (AD) is the most common type of 
age-related dementia, affecting approximately 24 million 
people worldwide, with the number of patients doub ling 
every 20 years as a consequence of the ageing popula tion.1 
This pandemic scenario will have not only a pro found 
health and emotional influence on affected indivi-
duals and their families, but will also place a substantial 
econom ic burden on society.
The disease is characterized by progressive loss of cog-
nitive abilities, severe neurodegeneration, and promi-
nent neuroinflammation.2 Neuropathological hall marks 
include proteinous aggregates in the form of senile 
plaques, which are enriched in amyloid-β (Aβ) pep tides, 
and neurofibrillary tangles (NFTs), consisting of hyper-
phosphorylated tau.3 Dominant genetic effects of muta-
tions in amyloid precursor protein (APP),  presenilin-1 
(PS1) or PS2 are responsible for the early-onset or fa milial 
form of AD. These mutations have been shown to pro-
foundly alter APP metabolism, favouring the produc-
tion of aggregation-prone Aβ species, and such findings 
formed the basis of the ‘amyloid cascade hypothesis’ of 
AD pathogenesis.4 This broadly accepted hypo thesis 
states that the generation of neurotoxic Aβ peptides 
by β-secretase and γ-secretase constitute the cause of 
AD pathophysiology, with all other disease hallmarks 
develop ing as a consequence of this event.
Although the amyloid cascade hypothesis is likely to 
hold true for the familial form of the disease, increas-
ing evidence suggests that the mechanisms underlying 
late-onset AD—the sporadic disease form that accounts 
for the vast majority of AD cases—could be different.5 
For example, in addition to the ε4 allele of the apolipo-
protein E gene (APOE)6—a well-known risk factor for 
AD—recent genome-wide association studies identi-
fied significant correlations between polymorphisms 
in genes of the innate immune system and incidence of 
late-onset AD.7,8 By contrast, no such correlation was 
found between polymorphisms in genes encoding APP 
or γ-secretase and incidence of late-onset AD.9 Together 
with the observation that inflammatory mediators are 
abundantly present in affected brain areas10,11 and plasma 
of patients with AD,12 these newly identified risk factors 
imply that alterations in innate immunity might have 
a key role in the disease aetiology, rather than being a 
passive reaction to Aβ-related neuropathology.
In this article, we integrate experimental data focused 
on neuroinflammation with several other neuropatho-
logical aspects of the disease that have so far been con-
sidered to be secondary to Aβ-mediated neurotoxicity, 
and propose a sequence of neuropathological events 
that could lead to development of late-onset AD. This 
model unites many of the previously proposed mecha-
nisms underlying AD into a comprehensive view of 
how the neuropathology could evolve over decades. We 
first present the results that have provided the rationale 
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for this hypothesis, which are then complemented by 
broader literature and experimental evidence from 
animal and human studies.
Inflammation hypothesis of AD
Rationale
A large body of evidence has implicated inflammatory 
mediators and the innate immune system of the brain in 
the aetiology of AD, as discussed below. The precise role 
of inflammatory processes in the disease pathophysio-
logy has, however, been controversial, ranging from a 
possible disease cause, to a by-product of the disease, or 
even a beneficial response.13 
Our previous findings in mice showed that systemic 
administration of the viral mimic polyriboinosinic– 
polyribocytidilic acid (PolyI:C) during late gestation trig-
gered the expression of several inflammatory cytokines 
in the foetal brain,14 evoked a reduction in adult neuro-
genesis in the offspring that was accompanied by working 
memory impairments,14,15 and led to accelerated depo-
sition of aggregated proteins in the brains of the aged 
offspring.16 More recently, we demonstrated that upon 
second immune stimulation with PolyI:C in adulthood, 
prenatally challenged animals developed an AD-like 
pheno type.17 The ageing-associated progression of disease 
in these mice was in striking similarity to that described 
in patients with AD.2 In addition, systemic immune chal-
lenge in adult transgenic AD mice led to a strong aggra-
vation of the AD-like pathology,17 in agreement with the 
observation that both acute and chronic inflammation 
are associated with an increase in cognitive decline in 
patients with AD.18 Alterations in critical inflammatory 
mediators might, therefore, represent a process associated 
with the onset and progression of the disease in humans, 
as already suggested by Sheng et al. in 1996.19
The model
In wild-type mice, ageing is associated with increased 
deposition of proteins in the brain parenchyma, and 
this phenomenon is highly conserved among various 
species.16,20 Using 3D immunoelectron microscopy in 
aged wild-type mice we found that, surprisingly, these 
extracellular depositions originated from intracellular 
spheroid-like varicosities20 and were immunoreactive for 
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N-terminal and Aβ-containing APP fragments.21 Some of 
these structures had a budding-like morphology and con-
tained organelles, but many were detached from neurons 
and/or were being engulfed by microglia and astrocytes 
(Figure 1, step 1).20,21 This phenomenon could, therefore, 
conceivably reflect a conserved neuroprotective strategy 
of postmitotic neurons to overcome age-related accumu-
lation of misfolded, damaged or aberrantly cleaved pro-
teins.20 In line with this suggestion, a prenatal immune 
challenge with its chronic elevation of proinflammatory 
cytokines17 accelerated the formation of these axonal bud-
dings, and induced the accumulation of mitochondria 
and other organelles within these varicosities (Figure 1, 
step 2).20 A strikingly similar budding phenomenon has 
also been observed in aged rhesus monkeys,22 which serve 
as a primate model of late-onset AD.23
Chronic inflammation and cellular stress to neurons 
during ageing—owing to infection, disease, or age-
related changes—induce hyperphosphorylation and 
mis sorting of tau,17 which in turn is expected to destabi-
lize the microtubule–actin networks and impair axonal 
trans port.24 Such changes might cause the protein extru-
sion mechanism to decline or fail completely, thereby 
inducing focal axonal swellings and concomitant accu-
mulation of mitochondria and other organelles (Figure 1, 
step 3).25,26 Disturbed energy metabolism in the axon 
could induce further tau phosphorylation,27 an additional 
neuropathological event that probably facilitates the 
formation of paired helical filaments (PHFs; precursor 
elements of neurofibrillary tangles), as seen in double-
immune-challenged mice.17 This outcome would lead to 
further impairments in axonal transport, complete trans-
port blockade, and ultimately axonal leakage (Figure 1, 
step 4; Figure 2a).28 Loss of synaptic contacts and decline 
in cognitive performance constitute additional structural 
and functional consequences of axonal transport impair-
ments (Figure 1, step 4).17,29 A chronic inflammatory state 
also increases APP levels,17 which may be followed by 
accumulation of this protein in swollen axons (Figure 1, 
steps 2–4; Figure 2b).28
In parallel with its effect on neurons, chronic sys-
temic inflammation induces a prominent activation, or 
‘priming’, of microglial cells and extensive astrogliosis 
(Figure 1, step 3).17 Recruitment of microglia towards 
degenerative and/or leaking axons and axonal varicosi-
ties could, therefore, lead to over-activation of micro-
glia and production of local inflammatory ‘hot spots’ 
that would also be expected to negatively affect nearby 
neurons (Figure 1, step 5). Support for this scenario is 
provided by our findings in double-immune-challenged 
mice in which individual accumulations of APP seem 
to involve groups of several adjacent neurites, which are 
surrounded by activated microglia.17 Finally, these APP 
accumulations might represent a seed for other aggrega-
tion-prone peptides (Figure 1, step 5), as demonstrated 
in immune-challenged transgenic AD mice.17
On the basis of recent observations in the brains of 
patients with AD,28 we propose that axonal leakage and 
release of intracellular contents—especially from dense 
auto phagolysosomal vesicles30,31 (Figure 2c–e)—including 
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accumulated APP28 (Figure 2b,f) into the extra cellular 
matrix (Figure 2a,b) leads to substantial local production 
of aggregation-prone protein fragments. This scena rio is 
in agreement with the abundant presence of APP cleav-
age enzymes, such as cathepsin-D31 (Figure 2e), and the 
enrichment of various truncated Aβ fragments32 and 
diverse non-Aβ fragments of APP33,34 in senile plaques. 
In addition, electron micro scopy of human senile plaques 
revealed, in accordance with this proposal, an abun-
dance of mitochondria and other organelles, as well as 
degenerated neurites, in the plaque core.33,35 Finally, the 
pro inflammatory environment and concomitant loss of 
axons might lead to formation of NFTs and neuronal cell 
death (Figure 1, step 6). This suggestion is in agreement 
with the observation that formation of NFT-like struc-
tures in AD transgenic mice—importantly, in the absence 
of mutant human tau—was accompanied by aggravated 
Aβ deposition, prominent neuroinflammation and con-
siderable shrinkage of cortical areas.36 Loss of synaptic 
contacts combined with persistent inflammation-induced 
cellular stress probably contributes to initiation of the 
patho physiology in interconnected brain areas and the 
spread of the pathology across brain networks.
In the following sections, we summarize additional 
experimental data from the existing literature that 
support each of the proposed steps of the model.
Inflammation—a key player
Support for a key role for systemic inflammation in the 
aetiology of AD was first provided by a meta-analysis of 
17 epidemiological studies, which indicated that non- 
steroidal anti-inflammatory drugs might decrease the 
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Figure 1 | The inflammation hypothesis of late‑onset 
Alzheimer disease. a | During healthy ageing, a conserved 
protein extrusion mechanism compensates for ageing‑
dependent failures in protein clearance and degradation 
(step 1). Cellular stress to ageing neurons accelerates 
formation of varicosities and their extrusion into the 
extracellular matrix, where they are phagocytosed by 
surrounding glia (step 2). If aged neurons experience 
chronic inflammation, tau becomes hyperphosphorylated 
and is missorted to somatodendritic compartments, which 
impairs axonal transport (steps 2 and 3).  
b | Consequently, stress‑induced APP accumulates in 
axonal compartments and in larger swellings (step 3). 
Chronic inflammation also ‘primes’ microglia to 
subsequent immune challenges (step 3). Blockade of 
axonal transport leads to synaptic destabilization or loss, 
and is accompanied by formation of PHFs in neurites and 
membrane leakage at axonal swellings (step 4). Axonal 
leakage exposes cellular proteins to lysosomal 
proteinases, promoting formation of neurotoxic peptides. 
Hyperreactive microglia cannot properly remove dystrophic 
neurites, and create a toxic proinflammatory environment 
that affects surrounding neurons. Senile amyloid‑β plaques 
begin to form (step 5). In response to neuritic 
degeneration, caspase activation triggers formation of 
neurofibrillary tangles (step 6). Imbalances in excitatory–
inhibitory neurotransmission and the neurotoxic 
proinflammatory environment initiate pathology in 
interconnected brain areas. Abbreviations: APP, amyloid 
precursor protein; PHF, paired helical filament.
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risk of AD.37 This view is supported by two key findings 
from retrospective epidemiological studies: first, plasma 
levels of the inflammatory proteins C-reactive protein, 
α1-antichymotrypsin and IL-6 are increased long before 
clinical onset of AD and dementia;38,39 and second, epi-
sodes of infections are strongly correlated with increased 
a b
c
d
e
f DAPI/N-APP/Aβ
Figure 2 | Axonal swellings and leakage as a trigger of senile plaque formation in patients with Alzheimer disease.  
a | Experimental support that evolution of senile plaques starts with axonal swelling and varicosities (top row, arrows) and 
leakage from dystrophic axons (bottom row, arrows) in the cortex. b | Immunostaining of the cortex reveals small (left panels) 
and medium‑sized (right panels) plaque‑like accumulations (arrows) enriched for hyperphosphorylated tau (upper panels) 
and APP and/or amyloid‑β (lower panels). c | Autophagic vacuoles (arrowheads) loaded with proteins accumulate in 
dystrophic neurites. d | Immunogold staining shows enrichment of cathepsin‑D, the APP‑degrading enzyme, in autophagic 
vacuoles in swollen neurites. e,f | Dense staining of cathepsin‑D within late‑stage senile plaques (e) overlaps with staining of 
accumulated amyloid‑β (f). Abbreviation: APP, amyloid precursor protein. Parts a and b are reproduced, with permission, from 
Springer © Xiao, A. W. et al. Neurosci. Bull. 27, 287–299 (2011). Parts c and e are reproduced, with permission, from Elsevier 
Ltd © Nixon, R. A. & Yang, D. S. Neurobiol. Dis. 43, 38–45 (2011). Part d is reproduced, with permission, from Wolters Kluwer 
Health © Nixon, R. A. et al. J. Neuropathol. Exp. Neurol. 64, 113–122 (2005). Part f is reproduced from Krstic, D. et al. 
J. Neuroinflammation 9, 151 (2012), which is published under an open‑access license by Biomed Central.
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likelihood of a diagnosis of dementia.40 Randomized con-
trolled trials, however, failed to show a beneficial effect of 
anti-inflammatory drugs in patients with symptomatic 
AD or mild cognitive impairment.41,42 Nevertheless, 
extended treatment of asymptomatic individuals with the 
anti-inflammatory drug naproxen reduced the incidence 
of AD, supporting a beneficial effect of anti-inflammatory 
drugs only when administered in early, asymptomatic 
phases of the disease.43
Interestingly, patients with high plaque burden with-
out dementia—so-called high-pathology controls44,45—
show almost no evidence of neuroinflammation46–48 and 
neuro degeneration.46 These findings are in accordance 
with results from several transgenic mouse lines that 
express human versions of AD-inducing mutated genes, 
which show no evidence of strong neuroinflammatory 
responses nor widespread progressive neuronal cell 
death.49 Of further interest, Aβ1-42 levels in the brains of 
high- pathology controls were much higher than those in 
the brains of aged-matched patients with AD,50 in agree-
ment with a controversial proposal that Aβ1-42 may be 
protective rather than toxic,51 as further discussed below. 
In addition, PET imaging studies revealed that cogni-
tive status in patients with AD is inversely correlated 
with microglial activation, but not Aβ load.52,53 Finally, 
in accordance with the above mentioned genome-wide 
association studies,7,8 chronic inflammatory diseases and 
conditions in humans, including atherosclerosis, obesity, 
diabetes, depression, and periodontitis,54–60 all represent 
either risk factors for or correlate strongly with the risk 
of late-onset AD.
Aged and primed microglia
The increase in proinflammatory cytokines in the serum 
that accompanies systemic inflammation has been shown 
to play a fundamental part in communication between 
the brain and immune system. Such communication 
occurs through activation of central innate immunity and 
initiation of a behavioural response, known as sickness 
behaviour.61 Apart from endothelial cells—which have 
an important role in blood–brain communication62— 
microglia seem to be crucially involved in regulation 
of the brain’s response to systemic inflammation. For 
example, systemic inflammation in mice induced by the 
viral mimic PolyI:C,63 the bacterial endotoxin lipopoly-
saccharide (LPS)64,65 or by peripheral infusion of the 
proinflammatory cytokine IL-1β66 was shown to activate 
microglia and induce the expression of brain-derived pro-
inflammatory cytokines. In agreement with these find-
ings, sepsis induces microglial activation in humans.67 
Moreover, chronic or repeated systemic inflamma tion 
in mice primes microglia to induce an exaggerated 
 proinflammatory response to subsequent stimulations.68
Consistent with these findings, microarray data from 
aged human and murine brain tissue point to increased 
transcriptional activity of genes related to cellular stress 
and inflammation in the course of ageing,10,69,70 a state 
that has been termed ‘inflammaging’.71 Hence, the obser-
vation that sickness behaviour at young age is relatively 
benign, whereas systemic inflammation in the elderly 
can lead to delirium,72 could be explained by an age-
associated priming of microglia.73,74 In rodents, acute 
systemic infection in aged, but not young, animals leads 
to hippocampus-dependent cognitive impairments,75,76 
and exaggerated and prolonged upregulation of the pro-
inflammatory cytokine IL-1β.77,78 Chronic inflammatory 
conditions during ageing are, therefore, expected to pro-
foundly affect the response of microglia towards damage 
signals that are released by degenerating neurons.
A broadly accepted view holds that microglia are 
recruited to clear Aβ aggregates,79 but ablation of micro-
glia does not influence the formation and maintenance 
of Aβ deposits in a mouse model of AD.80 Similarly, after 
uptake of soluble and fibrillary Aβ by microglia, a large 
fraction of both species are released without degrada-
tion.81,82 Microglia might instead be primarily recruited 
to clear the fragmented and/or apoptotic neurons and 
neurites within the senile plaques,83 as occurs during 
neurodevelopment.84 As proposed previously,33 micro-
glial involvement in internalization of Aβ aggregates 
could, therefore, be interpreted as part of the process of 
clearing degenerating neurites that contain misfolded 
and damaged proteins. 
Finally, besides being hyper reactive in AD,85 microglia 
may also become dysfunctional or senescent as disease 
progresses, as indicated by the association of fragmented 
microglia with tau pathology.86 This observation would 
also explain the attenuation of neuroinflammation in 
AD patients with increasing age,87 and supports the role 
of inflammation early in the pathogenesis of AD. Hence, 
in AD, a hyperreactive microglial state and increased 
secretion of proinflammatory mediators, combined with 
downregulated phagocytic functions, might lead to ineffi-
cient clearance of degenerated neurites. Impaired clear-
ance mechanisms may produce not only a neurotoxic 
environment for surrounding neurons, but also a local 
‘hot spot’ for accumulation of aggregation-prone peptides.
Early cytoskeletal impairments
Systemic administration of LPS, a potent inflamma-
tory agent, induces hyperphosphorylation of tau in 
 neurons88—a process that is mediated by activated micro-
glia.88–90 Similarly, a recent study showed that induced 
airway allergy in mice modified the brain inflammatory 
status and increased phosphorylation of tau.91 Given 
that phosphorylation of tau is crucial for regulation of 
microtubule stability and axonal transport,92 and that 
hyperphosphorylated tau not only affects the micro-
tubule network but also induces accumulation of fila-
mentous actin and formation of actin-rich rods,93 these 
observations could provide a link between inflamma-
tory processes and cytoskeletal abnormalities observed 
in postmortem examination of all AD cases.94 As previ-
ously proposed,95 these cytoskeletal abnormalities would 
affected axoplasmatic flow, as seen in patients with 
AD,96,97 and would impair the function of the Golgi appa-
ratus. Such an outcome could explain why this organelle 
has a fragmented and atrophic morphology in neurons 
of patients with AD.98 Interestingly, over expression of 
APOE ε4, as well as mutations in PS1 and APP, also affect 
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tau phosphorylation, axonal transport, and neuronal 
dystrophy99–102 in an Aβ-independent manner, which 
suggests a possible converging process underlying the 
familial and sporadic forms of the disease.
Finally, on the basis of analysis of an unbiased selec-
tion of postmortem human brains in the age range 
of 1–100 years, Heiko Braak and colleagues recently 
reported that tau-related neuronal changes appeared 
considerably earlier than did amyloid deposition, and 
that in more than half of investigated cases, abnormal 
tau protein occurred without the presence of Aβ depos-
its.103 These observations indicate that impairments in 
neuronal integrity owing to hyperphosphorylation of 
tau could constitute an early neuropathological event 
that precedes deposition of the classical AD hallmarks, 
potentially by decades.
Inflammation and cellular stress
Numerous inflammatory stimuli, such as IL-1β and 
IFN-γ, induce an increase in protein synthesis through 
the mTOR (mammalian target of rapamycin) signal-
ling pathway.104 A large fraction of newly generated 
proteins, however, are defective in folding, translation, 
and/or assembly. This inflammation-induced pool of 
damaged proteins are selectively degraded through the 
immunoproteasome105—a fast-acting proteasome variant 
that protects cells from the damaging effects of neuro-
inflammatory processes associated with ageing.106 In the 
brains of elderly individuals, aberrant, chronic elevation of 
inflammatory cytokines, which can result from persistent 
infections or inflammatory conditions, could conceiv-
ably impair or even inhibit immuno proteasome activity 
in ageing neurons,107 thereby enhancing the intracellular 
accumulation of misfolded or damaged proteins.
Immune challenge either by the bacterial mimic LPS 
or by direct application of IL-1β results in pronounced 
increase in APP synthesis in primary cultured neurons19,108 
as well as in the brains of rats and mice.19,109 Furthermore, 
several studies have provided experimental evidence that 
traumatic head injury in rodents and humans can result 
in significant elevation in APP levels,110,111 as well as Aβ 
generation and amyloid plaque deposition.112,113 In line 
with the high turnover, rapid anterograde transport, and 
processing of APP in distal compartments,114–116 geneti-
cally induced fibre tract degeneration in the gracile axonal 
dystrophy mouse provokes rapid axonal accumulation of 
APP and Aβ.117 Moreover, disruption of axonal and den-
dritic transport following impaired lysosomal proteo-
lysis is accompanied by increased levels of C-terminally 
cleaved APP fragments,118 which indicates that a combina-
tion of increased synthesis and impaired axonal transport 
of APP induces its rapid accumulation in neurites with 
subsequent aberrant cleavage. Notably, however, APP was 
recently shown to be required for maintenance of distal 
synaptic connections in APP/APLP2 knockout mice.119 
Hence, the increase in APP synthesis—so far exclusively 
considered as a trigger of accelerated production of 
‘neuro toxic’ Aβ peptides—may be a physiological reac-
tion of neurons to ensure stabilization of their synapses 
under stress conditions.
From varicosities to degeneration
The axonal enlargements described above that involve 
accumulation of multiple axonal cargoes and cyto-
skeletal proteins occur in transgenic AD mice,120,121 aged 
monkeys,22,122 and patients with AD,123 and precede the 
typical disease-related pathology. Complementing these 
findings, Xiao and colleagues recently showed that 
extensively swollen axons and varicosities, accompanied 
by pronounced axonal leakage, are associated with the 
origin and development of neuritic plaques in patients 
with AD28 (Figure 2a,b).
Swollen axons and varicosities in patients with AD 
contain high levels of APP28 and autophagic vacuoles that 
are enriched in PS1,123 cathepsin-D and cathepsin-B124—
lysosomal proteases with β-secretase activity125—as well 
as other lysosomal proteins. It is plausible, therefore, that 
the release of intracellular contents into the extracellular 
matrix via axonal leakage28 could bring APP into close 
proximity with APP-specific proteases. Aberrant APP 
processing at these locations is in agreement with the 
findings that Aβ plaques in patients with AD contain not 
only Aβ1–40 and Aβ1–42, but also substantial amounts of 
truncated Aβ peptides,32 as well as large amounts of APP 
and its non-amyloidogenic fragments.33,34 Interestingly, 
only truncated Aβ peptides isolated from the brains of 
patients with AD formed dimers,32 which are suggested 
to be principal neurotoxic species of Aβ.126 The pro-
posed scenario of plaque formation could also explain 
the increase in aberrantly cleaved (by cathepsin-D) 
fragments of Apo-E that are observed in patients with 
AD.127,128 Hence, in contrast to the familial form, in late-
onset AD, aberrant processing of accumulated APP seems 
to be secon dary to inflammation-induced axonopathy 
(Figure 2). In addition, physiologically produced Aβ1–42 
peptide may not represent the neurotoxic Aβ species, 
but an acute-phase reactant that is triggered by ongoing 
 neurodegenerative processes, as suggested previously.51
Although axonal degeneration precedes and may pre-
cipitate plaque formation, pronounced cell death and 
progressive neurodegeneration are late features in AD. 
Therefore, certain transport processes might remain 
active at early stages of the disease, despite the overt 
axonopathy and amyloid plaque deposition. Indeed, 
in a transgenic mouse model of AD, dystrophic axons 
associated with Aβ plaques remained continuous and 
connected to viable neuronal somata.129 Nevertheless, 
the lack of stabilizing presynaptic proteins, including 
APP,119 is expected to trigger synaptic disconnection—
a well-described feature of early-stage AD patho-
physiology.130 Secondary impairments in mitochondrial 
transport and energy supply,131 and aberrant maturation 
of autophagic vacuoles,30 are likely to further promote 
axonal de generation and induce neuronal death.
Formation of neurofibrillary tangles
Dystrophic axons and dendrites associated with 
Aβ plaques are ideally placed to link Aβ with the 
 microtubule-stabilizing protein tau and NFT neuro-
pathology. Although NFTs can exist in the absence 
of Aβ accumulation,103 a widely accepted view is that 
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 amyloid-related changes precede the tau-associated 
neuro pathology.4 The direct or indirect mechanistic 
relation ship between these two AD hallmarks, however, 
has not yet been resolved. Moreover, investigations into 
the molecular link between amyloid and NFTs have 
mainly, if not exclusively, centred on the involvement of 
Aβ peptides on tau localization and phosphorylation.132
The observation that neuritic plaques develop gradu-
ally in the projection areas of NFT-bearing neurons133 
indicates that NFTs develop in neurons whose neurites 
are involved in the formation of senile plaques. Support 
for this idea has been provided by immunolabelling and 
postmortem tracing studies in brain tissue from patients 
with AD, which showed that dystrophic and swollen and/
or leaking neurites participating in plaque formation 
also contain hyperphosphorylated tau.134,28 In addition, 
caspase activation was shown to precede the formation 
of tau aggregates, and caspase-cleaved tau was sufficient 
to induce the formation of NFTs.135 Hence, similar to 
induction of caspase activation following axonal swell-
ing during traumatic axonal injury,136 caspase activa-
tion—and, thereby, NFT formation—might be triggered 
by axonal transport blockade or leakage.137
Notably, these data support the concept that NFTs form 
in response to the axonopathy with its aberrant accu-
mulation and cleavage of APP and concomitant plaque 
formation, and not as a consequence of Aβ pathology. 
In line with this view, in mice over-expressing mutated 
human tau, NFT formation is preceded by axonopathy 
in the absence of amyloid plaque formation.138 Moreover, 
genetic ablation of kinesin light chain 1, which induces an 
age-dependent axonopathy, is accompanied by tau hyper-
phosphorylation, as evaluated using several AD-specific 
tau antibodies.138
Conclusion
For the past two decades, the general assumption that the 
molecular mechanism underlying the genetically deter-
mined form of AD is identical to the one determining the 
late-onset variant of the disease has resulted in an almost 
exclusive focus of our experimental and translational 
research on Aβ species and its effects on neuronal integ-
rity and functions. However, despite more than 66,000 
publications, numerous clinical investigations, and inno-
vative drug developments, we remain unable to even slow 
disease progression. Re-evaluation of our knowledge of 
the late-onset form of AD, which accounts for the majority 
of patients, is therefore of highest priority. In this article, 
we have integrated numerous experimental findings with 
a focus beyond Aβ to propose a sequence of pathological 
events that might lead to development of late-onset AD 
in humans. We suggest naming this integrated view 
of how the neuropathology evolves over decades ‘the 
in flammation hypothesis of AD’, as inflammation induced 
by infection, disease, or age-related changes could be the 
main cellular stressor after 80 or more years of life. In 
addition, traumatic head injury, micro-strokes and other 
vascular dysfunctions associated with increased risk of 
AD probably trigger the pathological cascade described 
here via secondary neuroinflammatory reactions.
In summary, in late-onset AD—in contrast to the 
familial form of the disease—chronic inflammatory 
conditions may represent a major trigger of pathology 
by inducing phospho-tau-related cytoskeletal abnormali-
ties and concomitant impairments of axonal transport. 
These changes could lead to age-dependent formation of 
axonal swellings, focal accumulation of mitochondria, 
and transport and degradation of organelles. Membrane 
leakage at the sites of axonal swellings could serve as a 
seed for the formation of senile plaques, thereby trig-
gering an innate immune response of the brain. Axonal 
transport impairments would also affect the stability 
of distal synapses and facilitate the formation of NFTs. 
Together with persistent neuroinflammatory reactions, 
these changes are expected to lead to prominent neuro-
degeneration and the spread of pathology. We argue, 
therefore, that extra cellular Aβ plaques originate from 
intracellular APP accumulations and are secondary to 
degeneration of neurons. Consequently, therapeutic 
strategies to remove plaques using specific antibodies, 
or to prevent plaque formation through inhibition of 
β-secretase or γ-secretase, would have little—if any—
effect on disease initiation and probably also progres-
sion. Finally, we propose that the primary pathological 
event in AD is inflammation-induced and stress-induced 
mislocalization and hyperphosphorylation of tau, with 
subsequent impairment of axonal transport.
We are aware that the experimental results and obser-
vations reviewed here represent only a fraction of all 
the published data on late-onset AD, and that further 
investigations are needed to fully delineate the molecular 
mechanisms that initiate and drive the pathology in late-
onset AD. Hence we truly hope that scientists and clini-
cians will add their data to confirm, refine, adjust, and 
extend our proposed sequence of events. Nevertheless, 
we strongly believe that the proposed model with its solid 
experimental backup provides a first step for the initia-
tion and support of new research directions in the AD 
field beyond Aβ.
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